Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Serina Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Serina Therapeutics, Inc.’s stock price such as:

• Serina Therapeutics, Inc.’s current stock price and volume
• Why Serina Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for SER from analysts
• SER’s stock price momentum as measured by its relative strength

About Serina Therapeutics, Inc. (SER)

Before we jump into Serina Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson’s disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson’s and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.

Want to learn more about Serina Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Serina Therapeutics, Inc..

Serina Therapeutics, Inc.’s Stock Price as of Market Close

As of September 04, 2026, 4:00 PM, CST, Serina Therapeutics, Inc.’s stock price was $2.730.

Serina Therapeutics, Inc. is up 1.49% from its previous closing price of $2.690.

During the last market session, Serina Therapeutics, Inc.’s stock traded between $2.512 and $2.740. Currently, there are approximately 16.39 million shares outstanding for Serina Therapeutics, Inc..

Serina Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Serina Therapeutics, Inc. Stock Price History

Serina Therapeutics, Inc.’s (SER) price is currently up 12.81% so far this month.

During the month of September, Serina Therapeutics, Inc.’s stock price has reached a high of $2.740 and a low of $2.380.

Over the last year, Serina Therapeutics, Inc. has hit prices as high as $5.830 and as low as $1.220. Year to date, Serina Therapeutics, Inc.’s stock is up 42.71%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Serina Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 04, 2026, there were 0 analysts who downgraded Serina Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Serina Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Serina Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Serina Therapeutics, Inc. (SER) by visiting AAII Stock Evaluator.

Relative Price Strength of Serina Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 04, 2026, Serina Therapeutics, Inc. has a weighted four-quarter relative price strength of -0.78%, which translates to a Momentum Score of 50 and is considered to be Average.

Want to learn more about how Serina Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Serina Therapeutics, Inc. Stock Price: Bottom Line

As of September 4, 2026, Serina Therapeutics, Inc.’s stock price is $2.730, which is up 1.49% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Serina Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.